Intermittentsupplementation with rapamycin as a dietary restriction mimetic
Intermittent supplementation with rapamycin as a dietary restriction mimetic
Aging is a complex process associated with
accumulation of damage, loss of function and increased
vulnerability to disease, leading ultimately to death.
Despite the complicated etiology of aging, an important
discovery of recent years has been that simple genetic
alterations can cause a substantial increase in healthy
lifespan in laboratory model organisms [1]. Many of
these longevity-extending mutations down-regulate the
activity of the mTOR/S6K pathway [2-5] suggesting
that reduced Tor/S6K signaling promotes entry into
alternative phases normally entered during periods of
starvation. In fact, dietary restriction (DR), a reduction
in food intake without malnutrition, lowers Tor/S6K
signaling and extends the average and maximum life
span of a variety of organisms including yeast, flies,
worms, fish, and rodents [1]. In both rodents and
monkeys, it delays loss of function and reduces the
incidence of major diseases [1] and in humans it causes
a reduction in several metabolic factors and markers of
diseases associated with including diabetes, and
cardiovascular disease and cancer [6]. In yeast, downregulation of the Tor/S6 pathway was shown to be
important for the effects of DR on longevity and stress
resistance [7].
Recently, it has been demonstrated that supplementation
with rapamycin (an inhibitor of mTOR) started both at 9
and 20 months of life determines a small but significant
extension of average and maximal life span in
genetically heterogeneous male and female mice [8, 9].
However, in these studies rapamycin supplementation
did not change the distribution of causes of death, and
in particular did not reduced cancer
oncotarget impact Zoya Demidenko Dr. Zoya N. Demidenko Zoya N. Demidenko , Ph.D. is Executive Manager of the Oncotarget journal . Oncotarget publishes high-impact research papers of general interest and outstanding significance and novelty in all areas of biology and medicine: in translational, basic and clinical research including but not limited to cancer research, oncogenes, oncoproteins and tumor suppressors, signaling pathways as potential targets for therapeutic intervention, shared targets in different diseases (cancer, benign tumors, atherosclerosis, eukaryotic infections, metabolic syndrome and other age-related diseases), chemotherapy, and new therapeutic strategies. After earning her Ph.D. in molecular biology, Zoya was awarded a Fogarty post-doctoral Fellowship from the National Institutes of Health in Bethesda, MD. After successful completion of post-doctoral training, she continued her professional career at George Washington University and Albert Einstein School of Medicine . In 2005 she cofounded the startup company Oncotarget Inc. which is focused on the development of anti-aging and anti-cancer drugs. Her research interests include signal transduction, cell cycle and cellular senescence, and their pharmacological targeting. In 2009 she cofounded the publishing house Impact Journals which specializes in publishing scientific journals. In 2011 she was selected to be a Member of the National Association of Professional Women .
When public discuss contemporary medicine, precision plays one of the most significant roles and people’s lives are directly dependent on it. Hence, any researches pertaining to medicine are required to comply with the top standards. The problem today is that any recommendations of researches can be published online and used as a reference without being adequately verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality measure. That allows both readers and authors to quality-check publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a complete publications list with corresponding scores higher than 100 as well as reports discussed previously. Mikhail (Misha) Blagosklonny glad to share his new approach and hopes it provides the necessary help to anyone, who has interest in oncology.
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was released back in 2018 by Oncotarget and completed by various experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are willing to understand the very meaning of it. Based on the Altmetric website, the score relates to “how many people have been exposed to and engaged with a scholarly output.” Likewise, the paper about melanoma, was utilized for citations in different news articles 69 times. Moreover, it was quoted in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have seen a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is glad to have the chance to share with online customers this highly appreciated and top-quality information, that is trustworthy and reliable.
Comments
Post a Comment